Company intelligence / Profile preview
LightOx
Newcastle upon Tyne, England, United Kingdomlightox.co.uk ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
LightOx has developed a new class of light activated small molecule therapeutics designed to selectively target and kill cancer cells upon exposure to light. Their lead candidates are formulated for topical treatment of oral cancers. The company’s approach allows minimal off-target toxicity and the potential for joint diagnostic-treatment agents. Lead programs are preclinical; no clinical results have been published yet.
- Therapeutic areas
- OncologyInfectious DiseasesRheumatology
- Modalities
- Small moleculesAntibody-drug conjugates (ADCs)Fluorescent probes/drug-like compoundsHDAC inhibitor fusions
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Merck – distribution deal for research tools under Research Use Only model.
Beyond the preview
Go deeper on LightOx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LightOx.